Nektar Therapeutics (NKTR) Sees Early Weakness

September 27, 2016 9:50 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Nektar Therapeutics (NASDAQ: NKTR) is under heavy pressure this morning. Shares are down 8.6% on volume that is running 49x normal.

This morning, Bristol-Myers Squibb Company (NYSE: BMY) and Nektar Therapeutics announced a new clinical collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) with Nektar’s investigational medicine, NKTR-214, as a potential combination treatment regimen in five tumor types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and natural killer (NK) cells directly in the tumor micro-environment and increase exp



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment